N/A Completed N=120 Randomized Single-blind Treatment

TMS for Suicidal Crisis in Active Duty SMs

Suicide · Suicidal Ideation · Suicidal Impulses · Suicidal Intention

Source: ClinicalTrials.gov NCT03014362 ↗

Enrolled (actual)

120

Serious AEs

3.3%

Results posted

Sep 2022

Primary outcomePrimary: Change in Suicidal Ideation (Acute) — 0.12; 0.12 score on a scale

Summary

The purpose of this study is to determine if the use of Transcranial Magnetic Stimulation (TMS) provides rapid reduction and sustained attenuation of suicidal crisis. TMS is a treatment for suicidal crisis that is quicker, less invasive, better tolerated, and with fewer side effects than current treatments such as Electroconvulsive Therapy (ECT) and medication therapies. There will be 6 months of follow-up, in order to establish the ongoing and lasting therapeutic effect of TMS.

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Suicidal Ideation (Acute)	0.12; 0.12	—

Eligibility Criteria

Inclusion Criteria

All Active Duty SMs (regardless of sex, ethnicity, sexual or religious orientation) who are admitted to Eisenhower Army Medical Center (EAMC) Inpatient Psychiatric Service (IPS) with active suicidality or elevated risk for suicide regardless of most psychiatric diagnostic co-morbidity (see exclusion criteria). This includes in-patient admissions for suicidality and outpatient SMs with a Columbia-Suicide Severity Rating Scale (C-SSRS) score ≥3.
Age 18 to 60
Able to speak and read English.

Exclusion Criteria

Combative with staff.
Comatose/catatonia.
Incapacity owing to active mania or psychosis.
Epilepsy, multiple sclerosis, or cerebrovascular accident.
Non-removable metal in the head (Shrapnel; plates, aneurysm coils/clips; metal tattoos etc.)
Implantable devices (pacemakers, stimulators, etc.)
Schizophrenic or borderline personality.
Positive screen for pregnancy.
Already receiving TMS as a treatment for depression.
Non-English reading and speaking subjects

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03014362). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.